Matinas BioPharma (MTNB) Stock: Buy, Sell, or Hold?
MTNB - Matinas BioPharma Holdings, Inc.
$2.83
0.06 (2.17%)
▲
5d:
+16.94%
30d:
+1440.56%
90d:
+274.69%
WAIT
LOW Confidence
Analysis Updated: Oct 7, 2026 12:00 AM ET
Earnings: Nov 09, 2026
Get Alerted When MTNB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: MTNB is 48.2% above its trading range ($1.91). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: MTNB is 48.2% above its trading range ($1.91). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: MTNB is currently trading at $2.83, which is considered extended relative to its 30-day fair value range of $-0.27 to $1.91.
Technical Outlook: Technically, MTNB is showing sideways momentum. Immediate support is located at $0.15, while resistance sits at $3.15.
Market Sentiment: MTNB scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $30.00 (+960.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MTNB is showing sideways momentum. Immediate support is located at $0.15, while resistance sits at $3.15.
Market Sentiment: MTNB scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $30.00 (+960.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$-0.27 -
$1.91
Company Quality Score
31/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
15.8%
All Signals
- BEARISH: Price significantly overextended (+48.2% above its trading range)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 960.1% below Wall St target ($30.00)
- WARNING: Composite score 31/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$-0.27 -
$1.91
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.15
Resistance Level
$3.15
Current Trend
Sideways
Technical data as of
Oct 8, 2026
Fundamental Context
Wall Street Target
$30.00
(+960.1%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: October 08, 2026 6:22 PM ET
Data refreshes hourly during market hours. Next update: 7:22 PM
Data refreshes hourly during market hours. Next update: 7:22 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MTNB showing a specific setup today?
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
22 analysts |
$109 | 61 BUY |
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
27 analysts |
$92 | 44 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$285 | 40 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 69 BUY |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
17 analysts |
$37 | 48 HOLD |
